Announcement on Signing the "Drug Marketing Authorization Transfer Agreement"

Chongqing Reimei Pharmaceutical Co., Ltd.

Announcement No.: 2026-041

Announcement on Signing the "Drug Marketing Authorization Transfer Agreement"

The Company and the entire Board of Directors guarantee the truthfulness, accuracy, and completeness of the announcement content, and that there are no false records, misleading statements, or major omissions.

I. Transaction Overview

Chongqing Reimei Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Reimei Pharmaceutical") and Jiangxi Tianzhihai Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianzihai Pharmaceutical") recently signed a "Drug Marketing Authorization Transfer Agreement." According to this agreement, the Company will acquire the drug marketing authorization for Vitamin D2 Soft Capsules (Drug Approval Number H36021226, Specification 0.25mg (10,000 units), including all packaging specifications and future new packaging specifications for the product, hereinafter referred to as the "Agreement Product" or "Transaction Asset") held by Tianzhihai Pharmaceutical for RMB 28 million. This includes the drug registration approval, all existing global commercial and market rights, and all other rights related to the Agreement Product (excluding the national distribution rights for Chongqing Reimei Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Reimei Pharmaceutical, which were obtained from June 29, 2022, to July 12, 2033).

This transaction does not constitute a connected transaction, nor does it constitute a major asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies." According to the "Shenzhen Stock Exchange GEM Stock Listing Rules," the "Articles of Association," and other relevant regulations, this transaction does not require deliberation by the Company's Board of Directors or Shareholders' Meeting. The change of the drug marketing authorization holder requires approval from the National Medical Products Administration. There are no major legal obstacles to the implementation of this transaction.

II. Basic Information of the Transaction Counterparty

1. Transferor Name: Jiangxi Tianzhihai Pharmaceutical Co., Ltd.

2. Unified Social Credit Code: 91361100161859633T

3. Type: Other Joint Stock Limited Company (Unlisted)

4. Registered Address: No. 1 Tianhai Road, Dexing City, Jiangxi Province

5. Legal Representative: Zhu Tiancai

6. Registered Capital: RMB 40 million

7. Business Term: May 8, 2002, to May 7, 2052

8. Business Scope: Production and sales of granules, tablets, hard capsules, and soft capsules; cultivation of Chinese herbal medicine, domestic trade; international trade; drug research and development, and technical services. (Projects subject to approval according to law shall be carried out after approval by relevant departments).

9. Shareholder Information:

According to the "Shareholder Register of Unlisted Joint Stock Limited Companies" issued by Jiangxi United Registration and Settlement Co., Ltd. on May 29, 2026, provided by Tianzhihai Pharmaceutical, the shareholders of Tianzhihai Pharmaceutical and their respective shareholdings are as follows: